The information contained in this document and communicated verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be
copied, reproduced or further distributed to any person or published, in whole or in part, for any purpose.
The Presentation does not form any part of an offer of, or invitation to apply for, securities in Pharming Group N.V. (the "Company").
The Presentation speaks as of the date shown on the front cover. The Company assumes no obligation to notify or inform the recipient of any developments or changes occurring
after the date of this document that might render the contents of the Presentation untrue or inaccurate in whole or in part. In addition, no representation or warranty, express or
implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any use of any such information or opinions given
by the Company or by any of its directors, members, officers, employees, agents or advisers.
The Presentation contains forward-looking statements, including statements about our beliefs and expectations. These statements are based on our current plans, estimates and
projections, as well as our expectations of external conditions and events. Forward-looking statements involve inherent risks and uncertainties and speak only as of the date they
are made. The Company undertakes no duty to update these and will not necessarily update any of them in light of new information or future events, except to the extent
required by applicable law.
The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the
United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.
High Potential Pipeline
Lead
Optimization Phase I Phase II Phase III
Approval &
Commercialization Preclinical
RUCONEST® Acute Hereditary Angioedema (HAE)
rhC1 INH Acute Kidney Injury
rhC1 INH Pre-Eclampsia
RUCONEST® HAE Acute (IM)
a-Glucosidase Pompe
a-Galactosidase Fabry’s
RUCONEST® Life Cycle
rhC1 INH Franchise
Additional Platform Programs
RUCONEST® HAE Prophylaxis (ID)
Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).
Late- stage in-licensed
Leniolisib (Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).